Position in ANVS
as of Jun 30, 2026
· filed Aug 20, 2026
Position Value
$34,556
-$6,875 QoQ
Shares Held
18,579
0.0% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#29
of 61 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GILL CAPITAL PARTNERS, LLC holds $44,182 across 14 Biotechnology names. ANVS ranks #1 (78.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ANVS |
Annovis Bio, Inc.
This page
|
18,579 | $34,556 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
50 | $3,724 | |
| 3 | EDIT |
Editas Medicine, Inc.
|
425 | $1,377 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
18 | $981 | |
| 5 | MRNA |
Moderna, Inc.
|
14 | $980 | |
| 6 | ABCL |
AbCellera Biologics Inc.
|
100 | $785 | |
| 7 | BEAM |
Beam Therapeutics Inc.
|
15 | $514 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
2 | $481 |
All Filings in ANVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $34,556 | 18,579 | Shares | Sole | 2026-08-20 | |
| 2026-03-31 | $41,431 | 18,579 | Shares | Sole | 2026-04-13 | |
| 2025-12-31 | $64,283 | 18,579 | Shares | Sole | 2026-02-10 | |
| No filing history on record for this holder in this stock. | ||||||